KRAS and pancreatic intraductal papillary-mucinous neoplasm: None of the studies compared prospectively KRAS and GNAS mutations in liquid biopsy samples between two IPMN patient cohorts with different clinically IPMN risk stratifications (surgical resected vs. under surveillance) (Table S1).